logo

For the Inventor, By the Inventor

Kenilworth, NJ, United States of America

Feng Liang

This inventor holds 11 USPTO granted patents. Top assignee: The Florida State University Research Foundation, Inc.. Active years: 1995-2006.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Feng Liang. Retrieved from https://idiyas.com/inventor/feng-liang-vhjrwjzx

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 11

% Patents Active = 72.7

Average Co-Inventor Count = 6.7

ph-index = 5

Forward Citations = 68(Granted Patents)


Location History:

  • Tallahassee, FL (US) (1995)
  • Durham, NC (US) (1997 - 2002)
  • Kenilworth, NJ (US) (2003 - 2006)

Company Filing History:

goldMedal11 out of 853 
 
The Florida State University Research Foundation, Inc.
 patents

Years Active: 1995-2006

Loading Chart...
11 patents (USPTO):Explore Patents
1. 7019150 - 1-deoxy taxol analogs (2006-03-28),
2. 6861537 - Tricyclic and tetracyclic taxane intermediates (2005-03-01),
3. 6620950 - Method for the preparation of 1-deoxy baccatin III, 1-deoxy taxol and 1-deoxy taxol analogs (2003-09-16),
4. 6545168 - 1-deoxy baccatin III, 1-deoxy taxol and 1-deoxy taxol analogs and method for the preparation thereof (2003-04-08),
5. 6433189 - Tricyclic and tetracyclic taxane intermediates (2002-08-13),
6. 6278026 - Intermediates for tricyclic or tetracyclic taxanes (2001-08-21),
7. 6005120 - Tricyclic and tetracyclic taxanes (1999-12-21),
8. 5760252 - Synthetic process for the preparation of tricyclic and tetracyclic (1998-06-02),
9. 5637732 - Tricyclic and tetracyclic taxanes (1997-06-10),
10. 5618952 - Synthetic process for the preparation of tricyclic and tetracyclic (1997-04-08),
11. 5405972 - Synthetic process for the preparation of taxol and other tricyclic and (1995-04-11),

Title: Innovations by Inventor Feng Liang

Introduction

Feng Liang, an esteemed inventor based in Kenilworth, New Jersey, has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of taxane compounds. With an impressive portfolio of 11 patents, Liang's work showcases his dedication to advancing medical innovations that have the potential to impact cancer treatment.

Latest Patents

Among Liang's latest patents are the 1-deoxy taxol analogs, including 1-Deoxybaccatin III, 1-deoxytaxol, and their preparation methods. These patents highlight his focus on creating new analogs that can provide enhanced therapeutic benefits. Additionally, he has worked on the synthesis of tricyclic and tetracyclic taxane intermediates, which are crucial for the production of taxol and other important taxanes.

Career Highlights

Feng Liang is currently affiliated with the Florida State University Research Foundation, Inc., where he conducts research aimed at improving drug formulations and therapeutic strategies. His work is recognized within the academic and scientific communities, and he has been a key player in many transformative projects.

Collaborations

Liang's innovations have been supported by collaborations with notable colleagues, including Robert A. Holton and Carmen Somoza. These partnerships have facilitated the exchange of ideas and expertise, leading to advancements in taxane research and development.

Conclusion

In summary, Feng Liang's contributions to pharmaceutical chemistry through his 11 patents demonstrate his significant role as an inventor and researcher. His ongoing work at the Florida State University Research Foundation, Inc. continues to push the boundaries of drug development, particularly in the fight against cancer. With a focus on creating innovative solutions, Liang exemplifies the spirit of inventiveness and collaboration that drives scientific progress.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…